ReviewJACC. Advances2024
Rheumatic Heart Disease Burden in Africa and the Need to Build Robust Infrastructure.
Review in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy of retrograde and antegrade enemas in the management of low anterior resection syndrome in patients undergoing rectal resection: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Rheumatic heart disease in children and adolescents, part 1: epidemiology, pathogenesis and diagnosis.BMJ paediatrics open · 2026Review
- Prevalence of Early Rheumatic Heart Disease Among Asymptomatic Students in Underserved Communities in Ethiopia: Cross-Sectional Observational Study.JMIR public health and surveillance · 2026Observational
- Review
- Primary health care approach to rheumatic heart disease management.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026Review
- Acute rheumatic fever and rheumatic heart disease.Nature reviews. Disease primers · 2026Review
- Development-adjusted inequities and temporal trends in rheumatic heart disease burden across ASEAN countries, 2000-2023.Frontiers in cardiovascular medicine · 2026Article
- Bridging Knowledge Gaps in Rheumatic Heart Disease Prevention: A Narrative Review of Educational Interventions Across Resource-Limited Settings.Health services insights · 2026Review
- Molecular epidemiology of Plasmodium falciparum drug resistance and vaccine targets in high-transmission settings in Africa.Scientific reports · 2025Article
- Machine learning for classification of advanced rheumatic heart disease using electrocardiogram in cardiology ward.BMC cardiovascular disorders · 2025Article
- Global burden and trend of rheumatic heart disease among women of childbearing age, 1990-2021, with projection to 2040.BMC cardiovascular disorders · 2025Article
- Article
- Bridging Global Gaps in Cardiovascular Health: Catalyzing Action.JACC. Advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic heart disease (RHD) is an important public health problem in Africa. Mapping the epidemiology of RHD involves elucidating its geographic distribution, temporal trends, and demographic characteristics. The prevalence of RHD in Africa varies widely, with estimates ranging from 2.9 to 30.4 per 1,000 population. Factors contributing to this burden include limited access to health care, poverty, lack of research interest, and genetic fragility. Studies have highlighted differences in group A Streptococcus (GAS) incidence among different African countries, emphasizing the importance of effective monitoring and intervention strategies. RHD epidemiological mapping in Africa indicates regional differences and socioeconomic determinants. The high prevalence among females in most studies and among children underscores the urgency for targeted interventions. Diagnosing RHD in Africa faces challenges of inaccessibility of health facilities and trained personnel. Efforts to develop cost-effective and accessible diagnostic tools, such as mobile/portable echocardiography machines, molecular biomarkers such as Tenascin-C and microRNA expression profile shows promise for accurate diagnosis of RHD, but their validation and utilization is limited due to resource constraints. Furthermore, lack of an effective licensed vaccine for GAS causes significant retardation in RHD control in Africa. Addressing the burden of RHD in Africa and other low- and middle-income countries requires robust RHD biomarkers and effective vaccines. This review provides a comprehensive overview of the landscape of RHD in Africa, covering the bacteriology of GAS, the burden of GAS infections, exploring diagnostic avenues, challenges, and opportunities in RHD biomarkers, diagnosis, effective prevention strategies, and RHD management in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.